All stocks / DFPH
Starling Oncology, Inc. DFPH
Starling Oncology (DFPH): convertible notes mentioned in an 8-K in July 2026, 3 insider sales or sale notices in 90 days and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- DFP HOLDINGS LIMITED
- Market tier
- OTC Pink Limited
- Trading status
- Active
- Last trade
- Dec 11
The financial report, and what it means
Annual figures to 2025-12-31- Revenue
- $502,729,000
- Net loss
- ($60,606,000)
It spends more than it earns
Under strainCustomers paid it $502.7 million in the year. It lost $60.6 million. For every $1 that came in, about $1.12 went out.
- Cash and cash equivalents
- $33,565,000
- Net cash used in operating activities
- ($24,587,000)
It has cash for a while
SteadyIt had $33.6 million in the bank and used about $2 million a month. At that pace the money lasts about 16 months unless it borrows or sells more shares.
- Total assets
- $164,656,000
- Total liabilities
- $180,376,000
It owes more than it owns
Under strainEverything the company owns adds up to $164.7 million. Its debts and unpaid bills add up to $180.4 million. That is about $1.10 owed for every $1 owned.
What this adds up to
2 of 3 checks show strain. It spends more than it earns. It owes more than it owns. These are facts from the company's own reports, not a recommendation.
Signals
Chernett Jorey reported selling 2,851,061 shares for about $11,375,733 (Form 4, 2026-11-06).
Rule: Form 4 or Form 144 sale in the last 90 days. Source record
Estimated float about 89,180,233 shares as of 2026-11-03: 101,991,024 outstanding minus 12,810,791 held by 13 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
Hively Brad reported selling 298,853 shares for about $1,946,310 (Form 4, 2026-08-21).
Rule: Form 4 or Form 144 sale in the last 90 days. Source record
BRADFORD HIVELY filed notice of a proposed sale of 298,853 shares (Form 144, 2026-08-21).
Rule: Form 4 or Form 144 sale in the last 90 days. Source record
8-K filed 2026-07-07 mentions: convertible note.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
Common questions about DFPH
Does DFPH file reports with the SEC?
Yes. Starling Oncology files with the SEC under company number 0001799191. The most recent filing we hold is a 25-NSE dated 2026-11-13.
Source recordHow many DFPH shares are outstanding?
101,991,024 shares as of 2026-11-03, as reported to the SEC.
Source recordHas DFPH filed reports late?
We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.
Have DFPH insiders sold shares recently?
3 insider sales or sale notices were filed in the last 90 days. Most recent: Chernett Jorey reported selling 2,851,061 shares for about $11,375,733 (Form 4, 2026-11-06).
Source recordWho runs Starling Oncology?
Officers named in its insider filings: Robert Ross Carter (Chief Financial Officer), Kristin England (Chief Administrative Officer) and Jeffrey Langsam (Chief Clinical Officer).
Source recordIs Starling Oncology making money?
Customers paid it $502.7 million in the year. It lost $60.6 million. For every $1 that came in, about $1.12 went out. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)
Source record